Pfizer Marks a Major Milestone in the Fight Against Antimicrobial Resistance in the UAE
Press release
Pfizer announced the introduction of a novel treatment in the United Arab Emirates for adult patients with serious Gram-negative bacterial infections in the United Arab Emirates. This milestone marks a significant advancement in addressing antimicrobial resistance (AMR), a global health challenge that already affects millions of people every year.
Antimicrobial resistance occurs when bacteria and other microbes no longer respond to existing medicines, making infections harder to treat and increasing the risk of severe illness. Resistant Gram-negative infections can leave patients vulnerable with very limited treatment options. For patients and their loved ones, this can mean longer hospital stays, greater uncertainty, and emotional strain.
This newly introduced therapy is designed to restore effectiveness against some of the most resistant pathogens, addressing a critical unmet need in infectious disease management.
Serhat Yalcinkaya, Pfizer's Gulf Cluster Lead, said: “At Pfizer, our focus has always been on patients. Today’s milestone underscores our commitment to delivering scientific breakthroughs that change patients’ lives. For more than 175 years, Pfizer has been at the forefront of tackling infectious diseases, and our continued efforts to address antimicrobial resistance reflect both our responsibility and dedication to patients across the Gulf region.
We are proud to collaborate with healthcare providers, governments, and partners in the UAE to ensure patients have timely access to life-saving treatments today while safeguarding future generations,” he added.
This launch is part of Pfizer’s wider efforts to strengthen infectious disease preparedness in the Gulf region by collaborating with healthcare providers, governments, and communities to expand access and safeguard patient care.
© 2000 - 2025 Al Bawaba (www.albawaba.com)
Background Information
Pfizer
At Pfizer, it applies science and its global resources to improve health and well-being at every stage of life. It strives to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Its diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world’s best-known consumer products.
Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of its time. Consistent with its responsibility as the world’s leading biopharmaceutical company, it also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on them.
Check out our PR service
Subscribe
Sign up to our newsletter for exclusive updates and enhanced content
